Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

Californians are set to vote on a proposal to spend $300 million a year over the next 10 years for stem cell research. For some perspective on how big a deal this would be, the federal government spent $25 million last year. The ballot measure, known as Proposition 71, is being financially supported by a strong cadre of entertainers, business people, and others, including Nancy Reagan, as the New York Times reports today and would be a strong counteraction to the Bush administration’s ban on new stem cell lines. But is the Times overstating the number of potential beneficiaries of stem cell research? The paper writes, “half of California’s families are affected by one or more of the 70 diseases or conditions that could respond to stem cell therapies,” in which they include Alzheimer’s disease. (Approximately 500,000 Californians have Alzheimer’s disease.) But as the Washington Post reported in June, stem cells are an unlikely therapy for Alzheimers, which involves the loss of huge numbers and varieties of the brain’s 100 billion nerve cells. Lest California voters come to wonder just what they’ve been sold, it may be better to be up front about it in the first place.

0 comments about this story. Start the discussion »

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me